Use of nicorandil in cardiovascular disease and its optimization

Drugs

Volumn 71, Issue 9, 2011, Pages 1105-1119

  Horinaka, Shigeo ^a  

^a DOKKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

Angina pectoris; Nicorandil

Indexed keywords

ADENOSINE TRIPHOSPHATE SENSITIVE POTASSIUM CHANNEL; AMLODIPINE; DILTIAZEM; GLIBENCLAMIDE; GLYCERYL TRINITRATE; ISOSORBIDE MONONITRATE; MITOCHONDRIAL PERMEABILITY TRANSITION PORE; NICORANDIL; NITRIC OXIDE; PLACEBO; PROPRANOLOL; REACTIVE OXYGEN METABOLITE;

ACUTE CORONARY SYNDROME; ARTERY MUSCLE; AUTONOMIC NERVOUS SYSTEM; BOLUS INJECTION; CONGESTIVE HEART FAILURE; CONTINUOUS INFUSION; CORONARY ARTERY DISEASE; DIGESTIVE SYSTEM ULCER; DIZZINESS; DOSE RESPONSE; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART ARRHYTHMIA; HEART PROTECTION; HEMODIALYSIS PATIENT; HUMAN; INTRACORONARY INFUSION; ISCHEMIC HEART DISEASE; ISCHEMIC PRECONDITIONING; MALAISE; MOUTH ULCER; NONHUMAN; PERCUTANEOUS CORONARY INTERVENTION; PROGNOSIS; PROTEIN FUNCTION; RECOMMENDED DRUG DOSE; REVIEW; SINGLE DRUG DOSE; STABLE ANGINA PECTORIS; TREATMENT DURATION; UNSTABLE ANGINA PECTORIS; VARIANT ANGINA PECTORIS;

ANIMALS; ANTI-ARRHYTHMIA AGENTS; CARDIOVASCULAR DISEASES; HUMANS; ISCHEMIC PRECONDITIONING; KATP CHANNELS; NICORANDIL; NITRIC OXIDE; REACTIVE OXYGEN SPECIES;

ANGINA;

EID: 79959715387     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11592300-000000000-00000     Document Type: Review

References (117)

1. Boden WE, O'Rourke RA, Teo KK, et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med 2007 Apr 12; 356 (15): 1503-16. (Pubitemid 46588415)
2. Frye RL, August P, Brooks MM et al. A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med 2009 Jun 11; 360 (24): 2503-15.
3. Hochman JS, Lamas GA, Buller CE, et al. Coronary intervention for persistent occlusion after myocardial infarction. N Engl J Med 2006 Dec 7; 355 (23): 2395-407. (Pubitemid 44911017)
4. Henderson RA, Pocock SJ, Clayton TC, et al. Seven-year outcome in the RITA-2 trial: coronary angioplasty versus medical therapy. J Am Coll Cardiol 2003 Oct 1; 42 (7): 1161-70. (Pubitemid 37188334)
5. Fraker Jr TD, Fihn SD, 2002 Chronic Stable Angina Writing Committee, American College of Cardiology, American Heart Association. 2007 chronic angina focused update of the ACC/AHA 2002 guidelines for the management of patients with chronic stable angina: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines Writing Group to develop the focused update of the 2002 guidelines for the management of patients with chronic stable angina. J Am Coll Cardiol 2007 Dec 4; 50 (23): 2264-74.
6. Fox K, Garcia MA, Ardissino D, et al. Guidelines on the management of stable angina pectoris: executive summary: the Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Eur Heart J 2006 Jun; 27 (11): 1341-81. (Pubitemid 43998110)
7. Taira N. Nicorandil as a hybrid between nitrates and potassium channel activators. Am J Cardiol 1989 Jun 20; 63 (21): 18J-24J. (Pubitemid 19161045)
8. Kukovetz WR, Holzmann S, Braida C, et al. Dual mechanism of the relaxing effect of nicorandil by stimulation of cyclic GMP formation and by hyperpolarization. J Cardiovasc Pharmacol 1991 Apr; 17 (4): 627-33.
9. Holzmann S, Kukovetz WR, Braida C, et al. Pharmacological interaction experiments differentiate between glibenclamide- sensitive K+ channels and cyclic GMP as components of vasodilation by nicorandil. Eur J Pharmacol 1992 Apr 29; 215 (1): 1-7.
10. Kukovetz WR, Holzmann S, Pö ch G. Molecular mechanism of action of nicorandil. J Cardiovasc Pharmacol 1992; 20 Suppl. 3: S1-7.
11. Holzmann S. Cyclic GMP as possible mediator of coronary arterial relaxation by nicorandil (SG-75). J Cardiovasc Pharmacol 1983 May-Jun; 5 (3): 364-70. (Pubitemid 13080752)
12. Frampton J, Buckley MM, Fitton A. Nicorandil: a review of its pharmacology and therapeutic efficacy in angina pectoris. Drugs 1992 Oct; 44 (4): 625-55.
13. Meany TB, Richardson P, Camm AJ, et al. Exercise capacity after single and twice daily doses of nicorandil in chronic stable angina pectoris. Am J Cardiol 1989 Jun; 63: 66J-70J. (Pubitemid 19161053)
14. Weston AH, Longmore J, Newgreen DT, et al. The potassium channel openers: a new class of vasorelaxants. Blood Vessels 1990; 27 (2-5): 306-13. (Pubitemid 20365785)
15. Gelband CH, Silberberg SD, Groschner K, et al. ATP inhibits smooth muscle Ca2(+)-activated K+ channels. Proc Biol Sci 1990 Oct 22; 242 (1303): 23-8. (Pubitemid 20370903)
16. Escande D, Cavero I. K+ channel openers and 'natural' cardioprotection. Trends Pharmacol Sci 1992 Jul; 13 (7): 269-72.
17. Greenberg SS, Cantor E, Ho E, et al. Comparison of nicorandil- induced relaxation, elevations of cyclic guanosine monophosphate and stimulation of guanylate cyclase with organic nitrate esters. J Pharmacol Exp Ther 1991 Sep; 258 (3): 1061-71.
18. Rapoport RM, Murad F. Endothelium-dependent and nitrovasodilator- induced relaxation of vascular smooth muscle: role of cyclic GMP. J Cyclic Nucleotide Protein Phosphor Res 1983; 9 (4-5): 281-96. (Pubitemid 14119268)
19. Taniguchi J, Furukawa KI, Shigekawa M. Maxi K+ channels are stimulated by cyclic guanosine monophosphate- dependent protein kinase in canine coronary artery smooth muscle cells. Pflugers Arch 1993 May; 423 (3-4): 167-72. (Pubitemid 23137288)
20. Matsui T, Amano M, Yamamoto T, et al. Rho-associated kinase, a novel serine/threonine kinase, as a putative target for small GTP binding protein Rho. EMBO J 1996 May 1; 15 (9): 2208-16. (Pubitemid 26141137)
21. Carafoli E. Calcium pump of the plasma membrane. Physiol Rev 1991 Jan; 71 (1): 129-53.
22. Vrolix M, Raeymaekers L, Wuytack F, et al. Cyclic GMPdependent protein kinase stimulates the plasmalemmal Ca2+ pump of smooth muscle via phosphorylation of phosphatidylinositol. Biochem J 1988 Nov 1; 255 (3): 855-63. (Pubitemid 18263950)
23. Akai K, Wang Y, Sato K, et al. Vasodilatory effect of nicorandil on coronary arterial microvessels: its dependency on vessel size and the involvement of the ATP-sensitive potassium channels. J Cardiovasc Pharmacol 1995 Oct; 26 (4): 541-7.
24. Hongo M, Takenaka H, Uchikawa S, et al. Coronary microvascular response to intracoronary administration of nicorandil. Am J Cardiol 1995 Feb 1; 75 (4): 246-50.
25. Nakae I, Quan L, Hashimoto K, et al. Mechanism of the vasodilatory action of nicorandil on coronary circulation in dogs. Cardiovasc Drugs Ther 1994 Feb; 8 (1): 137-45. (Pubitemid 24164811)
26. Kojima M, Ban T. Nicorandil shortens action potential duration and antagonises the reduction of Vmax by lidocaine but not by disopyramide in guinea-pig papillary muscles. Naunyn Schmiedebergs Arch Pharmacol 1988 Feb; 337 (2): 203-12. (Pubitemid 18076719)
27. Yanagisawa T, Taira N. Effect of 2-nicotinamidethyl nitrate (SG-75) on membrane potentials of canine Purkinje fibers. Jpn J Pharmacol 1981 Jun; 31 (3): 409-17. (Pubitemid 11072685)
28. Hirose M, Tsujino N, Nakada T, et al. Mechanisms of preventive effect of nicorandil on ischaemia-induced ventricular tachyarrhythmia in isolated arterially perfused canine left ventricular wedges. Basic Clin Pharmacol Toxicol 2008 Jun; 102 (6): 504-14. (Pubitemid 351691965)
29. Antzelevitch C, Shimizu W, Yan GX, et al. Cellular basis for QT dispersion. J Electrocardiol 1998; 30 Suppl.: 168-75. (Pubitemid 28145056)
30. Kato T, Kamiyama T, Maruyama Y, et al. Nicorandil, a potent cardioprotective agent, reduces QT dispersion during coronary angioplasty. Am Heart J 2001 Jun; 141 (6): 940-3. (Pubitemid 32477005)
31. Ashikaga T, Nishizaki M, Arita M, et al. Opening of K(ATP) channel attenuates the increase in QT dispersion produced by the first balloon inflation during coronary angioplasty. Circ J 2002 May; 66 (5): 469-72.
32. Akagi T, Sarazawa K, Inai Y, et al. Continuous administration of nicorandil decreases QT dispersion during the chronic phase of acute myocardial infarction. Int Heart J 2006 May; 47 (3): 351-61. (Pubitemid 44082830)
33. Horinaka S, Kobayashi N, Yabe A, et al. Nicorandil protects against lethal ischemic ventricular arrhythmias and up-regulates endothelial nitric oxide synthase expression and sulfonylurea receptor 2 mRNA in conscious rats with acute myocardial infarction. Cardiovasc Drugs Ther 2004 Jan; 18 (1): 13-22. (Pubitemid 38992594)
34. Hara H, Horinaka S, Yabe A, et al. Suppressive effect of nicorandil in ventricular arrhythmias after reperfusion therapy in patients with acute myocardial infarction. J Cardiol 2007 Mar; 49 (3): 135-41.
35. Ueda H, Nakayama Y, Tsumura K, et al. Intravenous nicorandil can reduce the occurrence of ventricular fibrillation and QT dispersion in patients with successful coronary angioplasty in acute myocardial infarction. Can J Cardiol 2004 May 1; 20 (6): 625-9. (Pubitemid 38811581)
36. Patel DJ, Purcell HJ, Fox KM. Cardioprotection by opening of the K(ATP) channel in unstable angina. Is this a clinical manifestation of myocardial preconditioning? Results of a randomized study with nicorandil. CESAR 2 investigation (Clinical European Studies in Angina and Revascularization). Eur Heart J 1999 Jan; 20 (1): 51-7. (Pubitemid 29027526)
37. Hanai Y, Mita M, Hishinuma S, et al. A systematic review on the short-term efficacy and safety of nicorandil for stable angina pectoris in comparison with those of bblockers, nitrates and calcium antagonists [in Japanese]. Yakugaku Zasshi 2010 Nov; 130 (11): 1549-63.
38. Hughes LO, Rose EL, Lahiri A, et al. Comparison of nicorandil and atenolol in stable angina pectoris. Am J Cardiol 1990 Sep 15; 66 (7): 679-82. (Pubitemid 20285107)
39. Meeter K, Kelder JC, Tijssen JG, et al. Efficacy of nicorandil versus propranolol in mild stable angina pectoris of effort: a long-term, double-blind, randomized study. J Cardiovasc Pharmacol 1992; 20 Suppl. 3: S59-66.
40. Di Somma S, Liguori V, Petitto M, et al. A double-blind comparison of nicorandil and metoprolol in stable effort angina pectoris. Cardiovasc Drugs Ther 1993 Feb; 7 (1): 119-23. (Pubitemid 23111634)
41. Lai C, Onnis E, Solinas R, et al. A new anti-ischemic drug for the treatment of stable effort angina pectoris: nicorandil: comparison with placebo and isosorbide-5-mononitrate [in Italian]. Cardiologia 1991 Sep; 36 (9): 703-11.
42. Zhu WL, Shan YD, Guo JX, et al. Double-blind, multicenter, active-controlled, randomized clinical trial to assess the safety and efficacy of orally administered nicorandil in patients with stable angina pectoris in China. Circ J 2007 Jun; 71 (6): 826-33.
43. Dö ring G. Antianginal and anti-ischemic efficacy of nicorandil in comparison with isosorbide-5-mononitrate and isosorbide dinitrate: results from two multicenter, double-blind, randomized studies with stable coronary heart disease patients. J Cardiovasc Pharmacol 1992; 20 Suppl. 3: S74-81.
44. Sasaki J, Saeki Y, Kawasaki K, et al. A multicenter comparison of nicorandil and diltiazem on serum lipid, apolipoprotein, and lipoprotein levels in patients with ischemic heart disease. Cardiovasc Drugs Ther 1992 Oct; 6 (5): 471-4.
45. Guermonprez JL, Blin P, Peterlongo F. A double-blind comparison of the long-term efficacy of a potassium channel opener and a calcium antagonist in stable angina pectoris. Eur Heart J 1993 Jul; 14 Suppl. B: 30-4. (Pubitemid 23233988)
46. Ulvenstam G, Diderholm E, Frithz G, et al. Antianginal and anti-ischemic efficacy of nicorandil compared with nifedipine in patients with angina pectoris and coronary heart disease: a double-blind, randomized, multicenter study. J Cardiovasc Pharmacol 1992; 20 Suppl. 3: S67-73.
47. The SWAN Study Group. Comparison of the antiischaemic and antianginal effects of nicorandil and amlodipine in patients with symptomatic stable angina pectoris: the SWAN study. J Clin Basic Cardiol 1999; 2: 213-7.
48. Kishida H, Murao S. Effect of a new coronary vasodilator, nicorandil, on variant angina pectoris. Clin Pharmacol Ther 1987 Aug; 42 (2): 166-74. (Pubitemid 17135972)
49. Lablanche JM, Bauters C, Leroy F, et al. Prevention of coronary spasm by nicorandil: comparison with nifedipine. J Cardiovasc Pharmacol 1992; 20 Suppl. 3: S82-5.
50. Lablanche JM, Bauters C, McFadden EP, et al. Potassium channel activators in vasospastic angina. EurHeart J 1993 Jul; 14 Suppl. B: 22-4. (Pubitemid 23233986)
51. Kato K. Haemodynamic and clinical effects of an intravenous potassium channel opener: a review. Eur Heart J 1993 Jul; 14 Suppl. B: 40-7. (Pubitemid 23233990)
52. Tanaka K, Kato K, Takano T, et al. Acute effects of intravenous nicorandil on hemodynamics in patients hospitalized with acute decompensated heart failure. J Cardiol 2010 Nov; 56 (3): 291-9.
53. Minami Y, Nagashima M, Kajimoto K, et al. Acute efficacy and safety of intravenous administration of nicorandil in patients with acute heart failure syndromes: usefulness of noninvasive echocardiographic hemodynamic evaluation. J Cardiovasc Pharmacol 2009 Oct; 54 (4): 335-40.
54. Tsutamoto T, Kinoshita M, Nakae I, et al. Absence of hemodynamic tolerance to nicorandil in patients with severe congestive heart failure. Am Heart J 1994 Apr; 127 (4 Pt 1): 866-73.
55. Tsutamoto T, Kinoshita M, Hisanaga T, et al. Comparison of hemodynamic effects and plasma cyclic guanosine monophosphate of nicorandil and nitroglycerin in patients with congestive heart failure. Am J Cardiol 1995 Jun 1; 75 (16): 1162-5.
56. Larsen AI, Gøransson L, Aarsland T, et al. Comparison of the degree of hemodynamic tolerance during intravenous infusion of nitroglycerin versus nicorandil in patients with congestive heart failure. Am Heart J 1997 Sep; 134 (3): 435-41. (Pubitemid 27431247)
57. Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation 1986 Nov; 74 (5): 1124-36. (Pubitemid 17174962)
58. Bolli R. The late phase of preconditioning. Circ Res 2000 Nov 24; 87 (11): 972-83.
59. Piper HM, Garcñ a-Dorado D, Ovize M. A fresh look at reperfusion injury. Cardiovasc Res 1998; 38 (2): 291-300. (Pubitemid 28294147)
60. Di Lisa F, Menabò R, Canton M, et al. Opening of the mitochondrial permeability transition pore causes depletion of mitochondrial and cytosolic NAD+ and is a causative event in the death of myocytes in postischemic reperfusion of the heart. J Biol Chem 2001 Jan 26; 276 (4): 2571-5.
61. Hausenloy DJ. Signalling pathways in ischaemic postconditioning. Thromb Haemost 2009 Apr; 101 (4): 626-34.
62. Solaini G, Harris DA. Biochemical dysfunction in heart mitochondria exposed to ischaemia and reperfusion. Biochem J 2005 Sep 1; 390 (Pt 2): 377-94. (Pubitemid 41337100)
63. Kevin LG, Camara AK, Riess ML, et al. Ischemic preconditioning alters real-time measure of O2 radicals in intact hearts with ischemia and reperfusion. Am J Physiol Heart Circ Physiol 2003 Feb; 284 (2): H566-74. (Pubitemid 36142884)
64. Halestrap AP. Calcium, mitochondria and reperfusion injury: a pore way to die. Biochem Soc Trans 2006 Apr; 34 (Pt 2): 232-7.
65. Halestrap AP. What is the mitochondrial permeability transition pore? J Mol Cell Cardiol 2009 Jun; 46 (6): 821-31.
66. Costa AD, Jakob R, Costa CL, et al. The mechanism by which the mitochondrial ATP-sensitive K+ channel opening and H2O2 inhibit the mitochondrial permeability transition. J Biol Chem 2006 Jul 28; 281 (30): 20801-8. (Pubitemid 44115421)
67. Kuno A, Critz SD, Cohen MV, et al. Nicorandil opens mitochondrial K(ATP) channels not only directly but also through a NO-PKG-dependent pathway. Basic Res Cardiol 2007 Jan; 102 (1): 73-9. (Pubitemid 44939336)
68. Kloner RA, Shook T, Antman EM, et al. Prospective temporal analysis of the onset of preinfarction angina versus outcome: an ancillary study in TIMI-9B. Circulation 1998 Mar 24; 97 (11): 1042-5.
69. Ishihara M, Sato H, Tateishi H, et al. Implications of prodromal angina pectoris in anterior wall acute myocardial infarction: acute angiographic findings and long-term prognosis. J Am Coll Cardiol 1997 Oct; 30 (4): 970-5. (Pubitemid 27435889)
70. Deutsch E, Berger M, Kussmaul WG, et al. Adaptation to ischemia during percutaneous transluminal coronary angioplasty: clinical, hemodynamic, and metabolic features. Circulation 1990 Dec; 82 (6): 2044-51.
71. Abdallah Y, Wolf C, Meuter K, et al. Preconditioning with diazoxide prevents reoxygenation-induced rigor-type hypercontracture. JMol Cell Cardiol 2010 Jan; 48 (1): 270-6.
72. Tritto I, D'Andrea D, Eramo N, et al. Oxygen radicals can induce preconditioning in rabbit hearts. Circ Res 1997 May; 80 (5): 743-8. (Pubitemid 27181357)
73. Baines CP, GotoM, Downey JM. Oxygen radicals released during ischemic preconditioning contribute to cardioprotection in the rabbit myocardium. J Mol Cell Cardiol 1997 Jan; 29 (1): 207-16. (Pubitemid 27129144)
74. Ozcan C, Terzic A, Bienengraeber M. Effective pharmacotherapy against oxidative injury: alternative utility of an ATP-sensitive potassium channel opener. J Cardiovasc Pharmacol 2007 Oct; 50 (4): 411-8. (Pubitemid 350303819)
75. Sato T, Sasaki N, O'Rourke B, et al. Nicorandil, a potent cardioprotective agent, acts by opening mitochondrial ATP-dependent potassium channels. J Am Coll Cardiol 2000 Feb; 35 (2): 514-8. (Pubitemid 30125546)
76. Matsubara T, Minatoguchi S, Matsuo H, et al. Three minute, but not one minute, ischemia and nicorandil have a preconditioning effect in patients with coronary artery disease. J Am Coll Cardiol 2000 Feb; 35 (2): 345-51. (Pubitemid 30125523)
77. Matsuo H, Watanabe S, Segawa T, et al. Evidence of pharmacologic preconditioning during PTCA by intravenous pretreatment with ATP-sensitive K+ channel opener nicorandil. Eur Heart J 2003 Jul; 24 (14): 1296-303. (Pubitemid 36917700)
78. IONA Study Group. Effect of nicorandil on coronary events in patients with stable angina: the Impact Of Nicorandil in Angina (IONA) randomised trial. Lancet 2002 Apr 13; 359 (9314): 1269-75.
79. Louis AA, Manousos IR, Coletta AP, et al. Clinical trials update: The Heart Protection Study, IONA, CARISA, ENRICHD, ACUTE, ALIVE, MADIT II and REMATCH. Impact Of Nicorandil on Angina. Combination Assessment of Ranolazine In Stable Angina. ENhancing Recovery In Coronary Heart Disease patients. Assessment of Cardioversion Using Transoesophageal Echocardiography. AzimiLide post-Infarct surVival Evaluation. Randomised Evaluation of Mechanical Assistance for Treatment of Chronic Heart failure. Eur J Heart Fail 2002 Jan; 4 (1): 111-6.
80. Japanese Coronary Artery Disease (JCAD) Study Investigators. Current status of the background of patients with coronary artery disease in Japan. Circ J 2006 Oct; 70 (10): 1256-62.
81. Horinaka S, Yabe A, Yagi H, et al. Effects of nicorandil on cardiovascular events in patients with coronary artery disease in the Japanese Coronary Artery Disease (JCAD) study. Circ J 2010; 74 (3): 503-9.
82. Kitakaze M, Asakura M, Kim J, et al. Human atrial natriuretic peptide and nicorandil as adjuncts to reperfusion treatment for acute myocardial infarction (J-WIND): two randomised trials. Lancet 2007 Oct 27; 370 (9597): 1483-93. (Pubitemid 47625560)
83. Ito H, Taniyama Y, Iwakura K, et al. Intravenous nicorandil can preserve microvascular integrity and myocardial viability in patients with reperfused anterior wall myocardial infarction. J Am Coll Cardiol 1999 Mar; 33 (3): 654-60.
84. Ishii H, Ichimiya S, Kanashiro M, et al. Impact of a single intravenous administration of nicorandil before reperfusion in patients with ST-segment-elevation myocardial infarction. Circulation 2005 Aug 30; 112 (9): 1284-8. (Pubitemid 41266722)
85. Kawai Y, Hisamatsu K, Matsubara H, et al. Intravenous administration of nicorandil immediately before percutaneous coronary intervention can prevent slow coronary flow phenomenon. Eur Heart J 2009 Apr; 30 (7): 765-72.
86. Iwakura K, Ito H, Okamura A, et al. Nicorandil treatment in patients with acute myocardial infarction: a metaanalysis. Circ J 2009 May; 73 (5): 925-31.
87. Wu KC, Zerhouni EA, Judd RM et al. Prognostic significance of microvascular obstruction by magnetic resonance imaging in patients with acute myocardial infarction. Circulation 1998 Mar 3; 97 (8): 765-72. (Pubitemid 28135339)
88. Hombach V, Grebe O, Merkle N, et al. Sequelae of acute myocardial infarction regarding cardiac structure and function and their prognostic significance as assessed by magnetic resonance imaging. Eur Heart J 2005 Mar; 26 (6): 549-57. (Pubitemid 40461096)
89. Kasama S, Toyama T, Sumino H, et al. Long-term nicorandil therapy improves cardiac sympathetic nerve activity after reperfusion therapy in patients with first acute myocardial infarction. J Nucl Med 2007 Oct; 48 (10): 1676-82. (Pubitemid 47572715)
90. Kasama S, Toyama T, Hatori T, et al. Comparative effects of nicorandil with isosorbide mononitrate on cardiac sympathetic nerve activity and left ventricular function in patients with ischemic cardiomyopathy. Am Heart J 2005 Sep; 150 (3): 477.e1-477.e8.
91. Kang CS, Chen CC, Lin CC, et al. Effect of ATP-sensitive potassium channel agonists on sympathetic hyperinnervation in postinfarcted rat hearts. Am J Physiol Heart Circ Physiol 2009 Jun; 296 (6): H1949-59.
92. Sanada S, Node K, Asanuma H, et al. Opening of the adenosine triphosphate-sensitive potassium channel attenuates cardiac remodeling induced by long-term inhibition of nitric oxide synthesis: role of 70-kDa S6 kinase and extracellular signal-regulated kinase. J Am Coll Cardiol 2002 Sep; 40 (5): 991-7. (Pubitemid 34994997)
93. Horinaka S, Kobayashi N, Yagi H, et al. Nicorandil but not ISDN upregulates endothelial nitric oxide synthase expression, preventing left ventricular remodeling and degradation of cardiac function in Dahl salt-sensitive hypertensive rats with congestive heart failure. J Cardiovasc Pharmacol 2006 May; 47 (5): 629-35. (Pubitemid 44309654)
94. Sekiya M, Sato M, Funada J, et al. Effects of the long-term administration of nicorandil on vascular endothelial function and the progression of arteriosclerosis. J Cardiovasc Pharmacol 2005 Jul; 46 (1): 63-7. (Pubitemid 40917780)
95. Ishibashi Y, Takahashi N, Tokumaru A, et al. Effects of long-term nicorandil administration on endothelial function, inflammation, and oxidative stress in patients without coronary artery disease. J Cardiovasc Pharmacol 2008 Mar; 51 (3): 311-6. (Pubitemid 351450611)
96. Ishii H, Toriyama T, Aoyama T, et al. Efficacy of oral nicorandil in patients with end-stage renal disease: a retrospective chart review after coronary angioplasty in Japanese patients receiving hemodialysis. Clin Ther 2007 Jan; 29 (1): 110-22. (Pubitemid 46414024)
97. Nishimura M, Tokoro T, Nishida M, et al. Clinical potential of nicorandil to inhibit major cardiac events in hemodialysis patients with suspected myocardial ischemia. Nephron Clin Pract 2009; 111 (3): c212-21.
98. Nishimura M, Tokoro T, Nishida M, et al. Oral nicorandil to reduce cardiac death after coronary revascularization in hemodialysis patients: a randomized trial. Am J Kidney Dis 2009 Aug; 54 (2): 307-17.
99. Dikow R, Kihm LP, Zeier M, et al. Increased infarct size in uremic rats: reduced ischemia tolerance? J Am Soc Nephrol 2004 Jun; 15 (6): 1530-6. (Pubitemid 38679677)
100. Rostand SG, Brunzell JD, Cannon 3rd RO, et al. Cardiovascular complications in renal failure. J Am Soc Nephrol 1991 Dec; 2 (6): 1053-62.
101. Parfrey PS, Foley RN, Harnett JD, et al. Outcome and risk factors of ischemic heart disease in chronic uremia. Kidney Int 1996 May; 49 (5): 1428-34. (Pubitemid 26166417)
102. Herzog CA, Ma JZ, Collins AJ. Poor long-term survival after acute myocardial infarction among patients on longterm dialysis. N Engl J Med 1998 Sep 17; 339 (12): 841-3.
103. Hodgson DM, Zingman LV, Kane GC, et al. Cellular remodeling in heart failure disrupts K(ATP) channeldependent stress tolerance. EMBO J 2003 Apr 15; 22 (8): 1732-42. (Pubitemid 36460130)
104. Izumiya Y, Kojima S, Kojima S, et al. Long-term use of oral nicorandil stabilizes coronary plaque in patients with stable angina pectoris. Atherosclerosis 2011 Feb; 214 (2): 415-21.
105. Eguchi Y, Takahari Y, Higashijima N, et al. Nicorandil attenuates FeCl(3)-induced thrombus formation through the inhibition of reactive oxygen species production. Circ J 2009 Mar; 73 (3): 554-61.
106. Simpson D, Wellington K.Nicorandil: a review of its use in the management of stable angina pectoris, including highrisk patients. Drugs 2004; 64 (17): 1941-55. (Pubitemid 39263662)
107. Roland E. Safety profile of an anti-anginal agent with potassium channel opening activity: an overview. Eur Heart J 1993 Jul; 14 Suppl. B: 48-52. (Pubitemid 23233991)
108. Witchitz S, Darmon JY. Nicorandil safety in the long-term treatment of coronary heart disease. Cardiovasc Drugs Ther 1995 Mar; 9 Suppl. 2: 237-43.
109. Dunn N, Freemantle S, Pearce G, et al. Safety profile of nicorandil: prescription-event monitoring (PEM) study. Pharmacoepidemiol Drug Saf 1999 May; 8 (3): 197-205. (Pubitemid 29286532)
110. Reichert S, Antunes A, Trechot P, et al. Major aphthous stomatitis induced by nicorandil. Eur J Dermatol 1997; 7: 132-3. (Pubitemid 27102174)
111. Agbo-Godeau S, Joly P, Lauret P, et al. Association of major aphthous ulcers and nicorandil. Lancet 1998 Nov 14; 352 (9140): 1598-9. (Pubitemid 28515250)
112. Gupta A, Morris G. Major aphthous ulcers induced by nicorandil. Age Ageing 2000 Jul; 29 (4): 372-3. (Pubitemid 30487931)
113. Shotts RH, Scully C, Avery CM, et al. Nicorandil-induced severe oral ulceration: a newly recognized drug reaction. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1999 Jun; 87 (6): 706-7.
114. Watson A, Al-Ozairi O, Fraser A, et al. Nicorandil associated anal ulceration. Lancet 2002 Aug 17; 360 (9332): 546-7. (Pubitemid 35232111)
115. Watson A, Suttie S, Fraser A, et al. Nicorandil associated anal ulceration. Colorectal Dis 2004 Sep; 6 (5): 330-1. (Pubitemid 39236530)
116. Toquero L, Briggs CD, Bassuini MM, et al. Anal ulceration associated with Nicorandil: case series and review of the literature. Colorectal Dis 2006 Oct; 8 (8): 717-20. (Pubitemid 44363598)
117. Egred M. Nicorandil-associated ulcerations. Eur J Gastroenterol Hepatol 2007 May; 19 (5): 395-8 (Pubitemid 46596692)